New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
05:33 EDTGSK, WTWStocks with implied volatility movement; GSK WTW
Stocks with implied volatility movement; GlaxoSmithKline (GSK) 16, Weight Watchers (WTW) 64 according to iVolatility.
News For GSK;WTW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
16:20 EDTWTWOn The Fly: Top stock stories for Monday
Subscribe for More Information
12:16 EDTWTWOn The Fly: Top stock stories at midday
Subscribe for More Information
09:15 EDTWTWOn The Fly: Pre-market Movers
Subscribe for More Information
07:40 EDTWTWWeight Watchers has attracted hedge fund suitor, NY Post reports
Subscribe for More Information
July 2, 2015
18:37 EDTGSKViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
June 26, 2015
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
07:14 EDTWTWWeight Watchers price target lowered to $4 from $5 at Credit Suisse
Subscribe for More Information
June 25, 2015
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
June 23, 2015
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
07:03 EDTWTWWeight Watchers to prepay portion of initial Tranche B-1 term loans
Weight Watchers commenced an offer to prepay at a discount to par up to $229M of Initial Tranche B-1 Term Loans outstanding under, and as defined in, and pursuant to the terms of, the Credit Agreement among the company, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent and an issuing bank, The Bank of Nova Scotia, as revolving agent, swingline lender and an issuing bank, and the other parties thereto. On June 22, 2015, the company accepted offers with a discount equal to or greater than 9.00% in respect of the Initial Tranche B-1 Term Loans. To complete the prepayment of the accepted offers, on June 26, 2015, the company will expend an aggregate amount of cash proceeds totaling approximately $77.2M plus an amount sufficient to pay accrued and unpaid interest on the amount to be prepaid to prepay approximately $84.9M of the Initial Tranche B-1 Term Loans, resulting in approximately $7.6 million in savings on the payment.
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use